Articles Tagged With:
-
Casirivimab + Imdevimab Injection
Casirivimab/imdevimab should be used to treat mild to moderate COVID-19 in adults and patients ≥ 12 years of age weighing at least 40 kg who have tested positive for SARS-CoV-2.
-
Multiple Sclerosis and Vascular Disease
Researchers evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with multiple sclerosis (MS) compared to healthy controls. MS patients exhibited less systemic vascular disease and more small vessel disease in the brain vs. controls.
-
Antibiotics for Traveler’s Diarrhea
International travel carries a risk of colonization by antimicrobial-resistant intestinal flora. Using quinolone, but not a macrolide, during travel further increases the risk of acquisition of extended-spectrum, beta-lactamase-producing Enterobacteriaceae.
-
The Effect of Age on Cholesterol-Lowering Therapy
Investigators analyzed data on the effect of age on cardiovascular (CV) outcomes and LDL cholesterol-lowering by alirocumab vs. placebo in recent acute coronary syndrome patients. They found alirocumab can lower the rate of CV events regardless of age — and produce more absolute benefit with age.
-
Healthcare Personnel COVID-19 Hospitalizations and Vaccine Prioritization
During the period of study, 5.9% of individuals hospitalized for COVID-19-related reasons were healthcare providers (HCP), with approximately one-third involving HCP who were not expected to directly contact patients.
-
Managing Appendicitis Medically
A multicenter, randomized trial showed that 10 days of antibiotics results in comparable outcomes as surgery. Three in 10 patients treated with antibiotics required surgery within 90 days.
-
Patients with Higher Renin Levels May Derive More Benefit from Angiotensin II Treatment
Serum renin concentration in patients with catecholamine-resistant vasodilatory shock may identify those for whom treatment with angiotensin II has improved intensive care unit outcomes.
-
Convalescent Plasma Therapy Does Not Affect Time to Clinical Improvement in Patients with Severe and Life-Threatening COVID-19
This was a randomized, open-label, multicenter trial of intravenous convalescent plasma infusion (4 mL/kg to 13 mL/kg) therapy. Convalescent plasma therapy was not associated with improvements in mortality or time to clinical improvement.
-
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
Novel COVID-19 Syndrome in Adults
Healthcare workers could be at risk of multisystem inflammatory syndrome linked to COVID-19, as the poorly understood condition, first seen in children, now is emerging in adults.